Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.7.0.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Income Statement [Abstract]      
Revenues $ 67,678 $ 60,740 $ 41,953
Other income 10,403 7,592 15,898
Total revenues 78,081 68,332 57,851
Cost of revenues 78,622 69,051 79,215
Gross loss 541 719 21,364
Operating expenses:      
Research and development 976,882 901,030 1,088,966
Less - research and development grants (344,056) (180,033) (129,220)
Research and development, net 632,826 720,997 959,746
Sales and marketing 336,287 245,756 136,770
General and administrative 571,110 807,277 809,927
Total operating expenses 1,540,223 1,774,030 1,906,443
Operating loss 1,540,764 1,774,749 1,927,807
Financial expenses (income), net 80,636 (1,094) 236,561
Net loss 1,621,400 1,773,655 2,164,368
Deemed dividend 1,842,061
Net loss attributable to holders of ordinary shares $ 1,621,400 $ 1,773,655 $ 4,006,429
Net loss attributable to holders of ordinary shares per share:      
Basic and diluted net loss attributable to holders of ordinary shares per share $ 0.12 $ 0.14 $ 1.24
Weighted average number of ordinary shares used in computing basic and diluted net loss per share 13,704,673 12,745,710 3,222,644